Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY)
Nirsevimab protected against RSV single and coinfections, with no evidence of replacement of RSV with other respiratory viruses. Clinical Trials Registration. NCT03979313.
Authors
- Douglas Arbetter (ORCID: https://orcid.org/0000-0002-3510-9706)
- D. T. Shen
- Deidre Wilkins (ORCID: https://orcid.org/0000-0002-7263-2600)
- Anastasia A. Aksyuk (ORCID: https://orcid.org/0000-0001-9778-3491)
- Bahar Ahani
- Vaishali S. Mankad
- Amanda Leach (ORCID: https://orcid.org/0000-0002-4638-8392)
- Elizabeth J. Kelly (ORCID: https://orcid.org/0000-0002-6988-8576)
- Laura L. Hammitt (ORCID: https://orcid.org/0000-0001-6051-1484)
- Mark T. Esser (ORCID: https://orcid.org/0000-0003-1689-3475)
- Vancheswaran Gopalakrishnan (ORCID: https://orcid.org/0000-0002-8704-035X)
- Ron Dagan (ORCID: https://orcid.org/0000-0002-8888-1046)
- Tonya Villafana (ORCID: https://orcid.org/0000-0001-7929-6374)
- Xavier Sáez‐Llorens (ORCID: https://orcid.org/0000-0002-1149-5905)
- Yue Chang (ORCID: https://orcid.org/0000-0003-2968-5843)
Institutions
- Ben-Gurion University of the Negev (IL)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- AstraZeneca (Australia) (AU)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (Switzerland) (CH)
- Secretaría Nacional de Ciencia, Tecnología e Innovación (PA)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Spain) (ES)
- AstraZeneca (Canada) (CA)
- AstraZeneca (United States) (US)
- Hospital del Niño (PA)
- City of Knowledge (PA)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1093/cid/ciae596
- Citations
- 13
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 5.03
Funders
- AstraZeneca
- Sanofi